The United States of America, As Represented by the Secretary, Department of Health and Human Services

Sanaria Inc.

Massachusetts Institute of Technology

University of Pittsburgh

Oxford University Innovation Ltd

Antigen Discovery, Inc.

The Chancellor, Masters and Scholars of the University of Oxford

Robert Seder

Geoffrey Lynn

Stephen L Hoffman

Leonard William Seymour

Azza Idris

Neville Kisalu

Barbara Flynn

Philip L Felgner

Alexander K Shalek

Mario Roederer

Travis K Hughes

Marc H Wadsworth, Ii

Rachel Vistein

Joseph J Campo, Jr

Joseph Francica

Joanne L Flynn

Patricia Darrah

Lawrence Wang

Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.

Expression vector delivery system and use thereof for inducing an immune response

Antibodies and antigen binding fragments that specifically bind tocircumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit ainfection.

Neutralizing antibodies tocircumsporozoite protein and their use

Embodiments of a novel platform for delivering a peptide antigen to a subject to induce an immune response to the peptide antigen are provided. For example, nanoparticle polyplexes are provided that comprise a polymer linked to a peptide conjugate by an electrostatic interaction. The conjugate comprises a peptide antigen linked to a peptide tag through an optional linker. An adjuvant may be included in the nanoparticle polyplex, linked to either the polymer or the conjugate, or admixed with the nanoparticles. The nanoparticle polyplex can be administered to a subject to induce an immune response to the peptide antigen.

Peptide vaccine formulations and use thereof for inducing an immune response

Provided herein are compositions and methods for therapeutic and/or prophylactic treatment of an intracellular bacterial infection in a subject in need thereof, comprising one or more modulating agents, wherein the one or more modulating agents increase expression of IFNγ, IL-2, TNF, and/or IL-17 in systemic and/or lung T cells. In some embodiments, the increase of expression of IFNγ, IL-2, TNF, and/or IL-17 occurs in lung T cells. The lung T cells can be lung resident T cells or systemic T cells that are recruited to the lung. In some embodiments, the T cells are CD4+ and/or CD8+ T cells. In some embodiments, the intracellular bacterial infection is a(MTB) infection.

Compositions and methods for treating bacterial infections

Antibodies and antigen binding fragments that specifically bind tocircumsporozoite protein and neutralizeare disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit ainfection.

Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected againstcaused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against-caused malaria.

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines

Growing community of inventors

Chevy Chase, MD, United States of America

Robert Seder